Massimo Pregnolato

Prof. Massimo Pregnolato

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MTMarco Terreni
Marco Terreni
MTMarina Taccani
Marina Taccani
MPMassimo Pregnolato
Massimo Pregnolato
The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases. After a careful examination of these phenomena and multiple mechanisms that make certain bacteria resistant to specific antibiotics that were originally effective in the treatment of infections caused by the same pathogens, possible strategies to stem antibiotic resistance are analyzed. This paper, therefore, focuses on the most promising new chemical compounds in the current pipeline active against multidrug-resistant organisms that are innovative compared to traditional antibiotics: Firstly, the main antibacterial agents in clinical development (Phase III) from 2017 to 2020 are listed (with special attention on the treatment of infections caused by the pathogens Neisseria gonorrhoeae, including multidrug-resistant isolates, and Clostridium difficile), and then the paper moves on to the new agents of pharmacological interest that have been approved during the same period. They include tetracycline derivatives (eravacycline), fourth generation fluoroquinolones (delafloxacin), new combinations between one β-lactam and one β-lactamase inhibitor (meropenem and vaborbactam), siderophore cephalosporins (cefiderocol), new aminoglycosides (plazomicin), and agents in development for treating drug-resistant TB (pretomanid). It concludes with the advantages that can result from the use of these compounds, also mentioning other approaches, still poorly developed, for combating antibiotic resistance: Nanoparticles delivery systems for antibiotics.

29 September 2004 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
DUDaniela Ubiali
Daniela Ubiali
SRSilvia Rocchietti
Silvia Rocchietti
FSFrancesca Scaramozzino
Francesca Scaramozzino
MTMarco Terreni
Marco Terreni
AAAlessandra M. Albertini
Alessandra M. Albertini
MPMassimo Pregnolato
Massimo Pregnolato

1 May 2000 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
Giovanni MagaGiovanni Maga
Giovanni Maga
DUDaniela Ubiali
Daniela Ubiali
RSRaul Salvetti
Raul Salvetti
MPMassimo Pregnolato
Massimo Pregnolato
SSSilvio Spadari
Silvio Spadari
Accumulating data have brought the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) into the forefront of antiretroviral therapy. Among the emerging compounds in this class, a particularly attractive one is efavirenz (Sustiva), recently approved for clinical use by the U.S. Food and Drug Administration. In the present study, the equilibrium dissociation constants for efavirenz binding to the different catalytic forms of human immunodeficiency virus type 1 RT as well as the association and dissociation rates have been determined using a steady-state kinetic approach. In addition, the same enzymological analysis has been extended to the thio-substituted analog, sefavirenz, which showed comparable activity in vitro against RT. Both compounds have been found to act as purely uncompetitive inhibitors at low drug concentrations (5 to 50 nM) and as mixed noncompetitive inhibitors at higher doses (50 to 500 nM). This behavior can be interpreted in terms of the relative affinities for the different catalytic forms of the enzyme. Both efavirenz and sefavirenz showed increasing affinities for the different forms of RT in the following order: free enzyme < (i.e., bound with lower affinity) binary RT–template-primer (TP) complex < ternary RT-TP-deoxynucleoside triphosphate (dNTP) complex. The rate of binding of the two inhibitors to the different enzyme-substrate complexes was well below the diffusion limit (on the order of 10 4 M −1 s −1 ); however, both inhibitors, when bound to the ternary RT-TP-dNTP complex, showed very low dissociation rates, on the order of 10 −4 s −1 for both compounds, typical of tightly binding inhibitors. Thus, efavirenz and its thio-substituted derivative sefavirenz appear to be peculiar in their mechanism of action, being selective tightly binding inhibitors of the ternary RT-TP-dNTP complex. Efavirenz is the first clinically approved NNRTI to show this property.

1 December 2000 in Il Farmaco
Verified
Journal Article
Closed access
MPMassimo Pregnolato
Massimo Pregnolato
MTMarco Terreni
Marco Terreni
DUDaniela Ubiali
Daniela Ubiali
GPGiuseppe Pagani
Giuseppe Pagani
PBPietro Borgna
Pietro Borgna
FZFabrizio Zampollo
Fabrizio Zampollo

25 November 2016 in Molecules
Verified
Journal Article
Open access
PDF file
Teodora BavaroTeodora Bavaro
Teodora Bavaro
GCGiulia Cattaneo
Giulia Cattaneo
ISImmacolata Serra
Immacolata Serra
Ilaria BenucciIlaria Benucci
Ilaria Benucci
MPMassimo Pregnolato
Massimo Pregnolato
MTMarco Terreni
Marco Terreni
This paper describes the immobilization of the neutral protease from Bacillus subtilis and its application in the regioselective hydrolysis of acetylated nucleosides, including building blocks useful for the preparation of anticancer products. Regarding the immobilization study, different results have been obtained depending on the immobilization procedure. Epoxy hydrophobic carriers gave a poorly stable derivative that released almost 50% of the immobilized protein under the required reaction conditions. On the contrary, covalent immobilization on a differently activated hydrophilic carrier (agarose) resulted in very stable enzyme derivatives. In an attempt to explain the obtained enzyme immobilization results, the hypothetical localization of lysines on the enzyme surface was predicted in a 3D structure model of B. subtilis protease N built in silico by using the structure of Staphylococcus aureus metalloproteinase as the template. The immobilized enzyme shown a high regioselectivity in the hydrolysis of different peracetylated nucleosides. A stable enzyme derivative was obtained and successfully used in the development of efficient preparative bioprocesses for the hydrolysis of acetylated nucleosides, giving new intermediates for the synthesis of capecitabine in high yield.

8 January 2012 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
DCDavide A. Cecchini
Davide A. Cecchini
RPRoberto Pavesi
Roberto Pavesi
SSSara Sanna
Sara Sanna
SDSimona Daly
Simona Daly
RXRoberto Xaiz
Roberto Xaiz
MTMarco Terreni
Marco Terreni